查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2049539

急性骨髓性白血病治療市場報告：按治療方法、藥物類型、給藥途徑和地區分類（2026-2034 年）

Acute Myeloid Leukemia Therapeutics Market Report by Treatment Type, Drug Type, Route of Administration, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球急性骨髓性白血病治療市場規模達14.852億美元。展望未來，IMARC Group預測，該市場將從2026年到2034年以10.11%的複合年成長率成長，到2034年達到36.263億美元。

急性骨髓性白血病（AML）是一種克隆性惡性腫瘤，會導致異常細胞快速增生。它主要侵犯骨髓和白血球（WBC），其特徵性症狀包括皮膚顏色變化、呼吸困難、疲倦、高燒、體重減輕、牙齦出血和鼻出血。 AML的常見治療方法包括化療、免疫療法、標靶治療、荷爾蒙療法和手術。這些治療方法通常會合併幹細胞移植，以提高療效、減少併發症並增強身體的免疫系統。

全球白血病發病率的不斷上升是市場成長的主要促進因素之一。此外，易患此類疾病的老年人口不斷成長也促進了市場成長。急性骨髓性白血病（AML）主要由影響血球生成的基因突變所引起。因此，聯合治療療法和標靶治療的日益普及，以及人們對癌症治療方案的認知不斷提高，也推動了市場成長。此外，改良型免疫毒素、烷化劑、單株抗體和多重抗藥性調變器的出現是推動市場成長的另一個主要因素。這些治療方法具有療效持久、療效顯著、能夠早期準確識別白血病細胞、降低癌症復發風險等優點。其他預計將進一步推動市場成長的因素包括腫瘤學領域的廣泛研發活動以及現有醫療基礎設施的顯著改善。

本報告解答的主要問題

  • 目前全球急性骨髓性白血病治療市場狀況如何？未來幾年我們預期會出現哪些趨勢？
  • 新冠疫情對全球急性骨髓性白血病治療市場產生了哪些影響？
  • 主要區域市場有哪些？
  • 市場如何依治療方法細分？
  • 依藥品類型分類，市場組成是怎樣的？
  • 依行政途徑分類的市場區隔如何？
  • 該產業價值鏈包含哪些不同階段？
  • 該行業的主要促進因素和挑戰是什麼？
  • 全球急性骨髓性白血病治療市場的結構是怎麼樣的？主要參與者有哪些？
  • 這個行業的競爭有多激烈？

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：急性骨髓性白血病治療藥物的全球市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依治療類型分類

  • Cytarabine
  • 細胞週期蛋白藥物
  • 烷化劑
  • 抗代謝物
  • 蛋白酪氨酸激酶抑制劑
  • 其他

第7章 市場區隔：依藥物類型分類

  • 小分子藥物
  • 生物製藥

第8章 市場區隔：依給藥途徑

  • 口服
  • 注射藥物

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Abbvie Inc.
    • Amgen Inc.
    • Bristol-Myers Squibb Company
    • Celgene
    • Roche Holding AG
    • Gilead Sciences Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
Product Code: SR112026A3129

The global acute myeloid leukemia therapeutics market size reached USD 1,485.2 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 3,626.3 Million by 2034, exhibiting a growth rate (CAGR) of 10.11% during 2026-2034.

Acute myeloid leukemia (AML) refers to a clonal malignancy leading to the rapid growth of abnormal cells. It primarily impacts the bone marrow and white blood cells (WBCs) and is characterized by the discoloration of skin, breathlessness, fatigue, high body temperatures, weight loss, bleeding gums and nosebleeds. Some of the commonly used AML therapies include chemo-, immuno-, targeted- and hormonal therapies and surgical procedures. These therapeutics are usually combined with stem cell transplants to increase the efficacy, minimize complications and strengthen the immune system of the body.

The increasing prevalence of leukemia across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such disorders, is also driving the market growth. AML is primarily caused by genetic mutations in the body that impacts the levels of blood cell production. In line with this, the widespread adoption of combination and targeted therapies and increasing awareness regarding the available alternatives for cancer treatment are also favoring the market growth. Additionally, the advent of improved immunotoxins, alkylating agents, monoclonal antibodies and multidrug-resistant modulators is another major growth-inducing factor. These therapeutics offer prolonged results, higher efficacy, early and accurate identification of leukemia cells and reduced chances of cancer relapse. Other factors, including extensive research and development (R&D) activities in the field of oncology, along with significant improvements in the existing healthcare infrastructure, are anticipated to drive the market further.

KEY MARKET SEGMENTATION:

Breakup by Treatment Type:

  • Cytarabine
  • Anthracycline Drugs
  • Alkylating Agents
  • Anti-Metabolites
  • Tyrosine Kinase Inhibitors
  • Others

Breakup by Drug Type:

  • Small Molecule Drugs
  • Biopharmaceuticals

Breakup by Route of Administration:

  • Oral
  • Injectables

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

COMPETITIVE LANDSCAPE:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Celgene, Roche Holding AG, Gilead Sciences Inc., Novartis AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How has the global acute myeloid leukemia therapeutics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global acute myeloid leukemia therapeutics market?
  • What are the key regional markets?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global acute myeloid leukemia therapeutics market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Acute Myeloid Leukemia Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Cytarabine
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Anthracycline Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Alkylating Agents
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Anti-Metabolites
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Tyrosine Kinase Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Small Molecule Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Biopharmaceuticals
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectables
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbvie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Amgen Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bristol-Myers Squibb Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Celgene
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 SWOT Analysis
    • 14.3.5 Roche Holding AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 Gilead Sciences Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Novartis AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sanofi S.A.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Takeda Pharmaceutical Company Limited
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Acute Myeloid Leukemia Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020-2025
  • Figure 3: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 4: Global: Acute Myeloid Leukemia Therapeutics Market: Breakup by Treatment Type (in %), 2025
  • Figure 5: Global: Acute Myeloid Leukemia Therapeutics Market: Breakup by Drug Type (in %), 2025
  • Figure 6: Global: Acute Myeloid Leukemia Therapeutics Market: Breakup by Route of Administration (in %), 2025
  • Figure 7: Global: Acute Myeloid Leukemia Therapeutics Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Acute Myeloid Leukemia Therapeutics (Cytarabine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Acute Myeloid Leukemia Therapeutics (Cytarabine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Acute Myeloid Leukemia Therapeutics (Anthracycline Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Acute Myeloid Leukemia Therapeutics (Anthracycline Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Acute Myeloid Leukemia Therapeutics (Alkylating Agents) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Acute Myeloid Leukemia Therapeutics (Alkylating Agents) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Acute Myeloid Leukemia Therapeutics (Anti-Metabolites) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Acute Myeloid Leukemia Therapeutics (Anti-Metabolites) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Acute Myeloid Leukemia Therapeutics (Tyrosine Kinase Inhibitors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Acute Myeloid Leukemia Therapeutics (Tyrosine Kinase Inhibitors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Acute Myeloid Leukemia Therapeutics (Others) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Acute Myeloid Leukemia Therapeutics (Others) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Acute Myeloid Leukemia Therapeutics (Small Molecule Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Acute Myeloid Leukemia Therapeutics (Small Molecule Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Acute Myeloid Leukemia Therapeutics (Biopharmaceuticals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Acute Myeloid Leukemia Therapeutics (Biopharmaceuticals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Acute Myeloid Leukemia Therapeutics (Oral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Acute Myeloid Leukemia Therapeutics (Oral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Acute Myeloid Leukemia Therapeutics (Injectables) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Acute Myeloid Leukemia Therapeutics (Injectables) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: North America: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: North America: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: United States: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: United States: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Canada: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Canada: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Asia-Pacific: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Asia-Pacific: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: China: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: China: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Japan: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Japan: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: India: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: India: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: South Korea: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: South Korea: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Australia: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Australia: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Indonesia: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Indonesia: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Others: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Others: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Europe: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Europe: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Germany: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Germany: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: France: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: France: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: United Kingdom: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: United Kingdom: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Italy: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Italy: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Spain: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Spain: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Russia: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Russia: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Others: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Others: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Latin America: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Latin America: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Brazil: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Brazil: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Mexico: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Mexico: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Others: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Others: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Middle East and Africa: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Middle East and Africa: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Middle East and Africa: Acute Myeloid Leukemia Therapeutics Market: Breakup by Country (in %), 2025
  • Figure 77: Global: Acute Myeloid Leukemia Therapeutics Industry: SWOT Analysis
  • Figure 78: Global: Acute Myeloid Leukemia Therapeutics Industry: Value Chain Analysis
  • Figure 79: Global: Acute Myeloid Leukemia Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Acute Myeloid Leukemia Therapeutics Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Breakup by Treatment Type (in Million USD), 2026-2034
  • Table 3: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Breakup by Drug Type (in Million USD), 2026-2034
  • Table 4: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
  • Table 5: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Acute Myeloid Leukemia Therapeutics Market: Competitive Structure
  • Table 7: Global: Acute Myeloid Leukemia Therapeutics Market: Key Players